Behavioral gender differences are reinforced during the COVID-19 crisis


Posted: 2021-09-29 19:00:00
Behavioral gender differences have been found for a wide range of human activities including the way people communicate, move, provision themselves, or organize leisure activities. Using mobile phone data from 1.2 million devices in Austria (15% of the population) across the first phase of the COVID-19 crisis, we quantify gender-specific patterns of communication intensity, mobility, and circadian rhythms. We show the resilience of behavioral patterns with respect to the shock imposed by a strict nation-wide lock-down that Austria experienced in the beginning of the crisis with severe implications on public and private life. We find drastic differences in gender-specific responses during the different phases of the pandemic. After the lock-down gender differences in mobility and communication patterns increased massively, while circadian rhythms tended to synchronize. In particular, women had fewer but longer phone calls than men during the lock-down. Mobility declined massively for both genders, however, women tended to restrict their movement stronger than men. Women showed a stronger tendency to avoid shopping centers and more men frequented recreational areas. After the lock-down, males returned back to normal quicker than women; young age-cohorts return much quicker. Differences are driven by the young and adolescent population. An age stratification highlights the role of retirement on behavioral differences. We find that the length of a day of men and women is reduced by 1 h. We interpret and discuss these findings as signals for underlying social, biological and psychological gender differences when coping with crisis and taking risks.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
4月 21, 2020 バイオアソシエイツ

Gilead社は調査中の化合物RemdesivirのCOVID-19に対する進捗を更新

Gilead Sciences社は、世界の保健当局と緊密に協力して、調査用化合物「Remdesivir(レムデシビル)」(画像)の実験的使用を通じ、新型コロナウイルス( COVID-19 )に対応していることを報告した。米国食品医薬品局(FDA)、疾病対策センター(CDC)、保健福祉省(DHHS)、米国立アレルギー感染症研究所(NIAID)、国防総省(DoD)- CBRN Medical、中国CDCおよび国家医療製品管理局(NMPA)、世界保健機関(WHO)、そして個々の研究者と臨床医と共同して、Gilead…

ゲスト 917人 と メンバー 7人 がオンラインです